Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.44
+0.02000.83%
Post-market: 2.40-0.0400-1.64%19:36 EDT
Volume:265.61K
Turnover:652.05K
Market Cap:24.34M
PE:-0.56
High:2.74
Open:2.45
Low:2.12
Close:2.42
52wk High:18.00
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:4.39
T/O Rate:2.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3427
EPS(LYR):-4.0377
ROE:-89.23%
ROA:-50.69%
PB:0.91
PE(LYR):-0.60

Loading ...

Atossa Says Novel Endoxifen-related Compounds Show Potent Preclinical Activity in ER-positive Breast Cancer Models

Reuters
·
Jul 28

Atossa Therapeutics Announces AACR Poster Presentation on (z)-endoxifen in Mccune-albright Syndrome

Reuters
·
Jul 21

Atossa Therapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
Jul 08

Atossa Therapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jul 07

Atossa Therapeutics closes registered direct offering raising USD 4.5 million upfront

Reuters
·
Jun 13

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 13

Top Midday Decliners

MT Newswires Live
·
Jun 12

Atossa Therapeutics Launches $16.5 Million Registered Direct Offering

MT Newswires Live
·
Jun 11

Atossa Therapeutics issues Series A and B warrants for 1,363,638 shares in registered direct offering at $3.3 each

Reuters
·
Jun 11

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 11

Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer

Reuters
·
May 27

Atossa Therapeutics Announces Asco 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across Esr1 Mutations and Ongoing Evangeline Phase 2 Trial

THOMSON REUTERS
·
May 27

Atossa says (Z)-endoxifen Duchenne muscular dystrophy review accepted for publication

Reuters
·
May 21

Atossa Therapeutics Inc expected to post a loss of $1.03 a share - Earnings Preview

Reuters
·
May 08

Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses

Reuters
·
May 08

Atossa presents preclinical (Z)-endoxifen data in Duchenne muscular dystrophy mouse models

Reuters
·
May 08

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 Operating Expenses USD 9.87 Million

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million

Reuters
·
May 08

Atossa Therapeutics shareholders approve reverse stock split authorization

Reuters
·
May 08